Search for content, post, videos

Novo Nordisk reports increased operating profit

Novo Nordisk increased operating profit in Danish kroner by 57 percent in the first six months of 2015 to DKK 26.3 billion.

16% local currency operating profit growth adjusted for the NNIT divestment

Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion.

  • Sales of Victoza® increased by 41% (22% in local currencies).
  • Sales of Levemir® increased by 28% (10% in local currencies).
  • Sales in North America increased by 35% (10% in local currencies).
  • Sales in International Operations increased by 26% (17% in local currencies).
  • Sales in Region China increased by 25% (3% in local currencies).

Gross margin improved by 2.2 percentage points in Danish kroner to 85.2% driven by a positive currency impact and product mix.

Operating profit increased by 57% in Danish kroner and by 30% in local currencies to DKK 26.3 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 16%.

Net profit increased by 35% to DKK 18.2 billion. Diluted earnings per share increased by 38% to DKK 7.02. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 22% respectively.

Source: Novo Nordisk

Leave a Reply

Your email address will not be published. Required fields are marked *

one × five =